ACADEMISCH ZIEKENHUIS LEIDEN

Their core work

Leiden University Medical Center (LUMC) is one of the Netherlands' leading academic hospitals, combining patient care with biomedical research across immunology, regenerative medicine, medical imaging, and clinical trials. They translate fundamental discoveries in areas like stem cell therapy, diabetes, and cancer genetics into clinical applications through large-scale European research programmes. LUMC operates major research infrastructures for structural biology, biobanking, and neuroinformatics, and trains the next generation of biomedical researchers through extensive Marie Skłodowska-Curie networks. Their work spans from molecular-level drug discovery to population-level health economics and disease prevention.

What they specialise in

How they've shifted over time

In their earlier H2020 participation (2015-2017), LUMC focused broadly on health economics, drug discovery, biotechnology, and computational neuroscience (human brain simulation, neuroinformatics, high performance computing), reflecting involvement in large-scale brain research infrastructure. By the later period (2018-2021), their focus shifted decisively toward translational clinical tools: biomarkers, magnetic resonance imaging, mesenchymal stem cells, induced pluripotent stem cells, and microbiome research. The emergence of EOSC and GDPR as recent keywords also signals growing involvement in research data infrastructure and compliance frameworks.

LUMC is moving from broad foundational research toward translational biomarker-driven medicine, combining advanced imaging with multi-omics diagnostics — making them an increasingly attractive partner for precision medicine and clinical validation projects.

How they like to work

LUMC operates as both a consortium leader and a highly active partner, coordinating 42 projects (27% of their portfolio) while participating in 107 others — showing they can drive research agendas and contribute specialist expertise equally well. With 1,260 unique consortium partners across 70 countries, they function as a major hub in European biomedical research networks rather than clustering around a small set of repeat collaborators. Their frequent involvement in large Research and Innovation Actions (76 RIA projects) and training networks (15 MSCA-ITN) means they are experienced in managing complex multi-partner consortia and mentoring early-career researchers.

LUMC has built one of the most extensive collaboration networks in European biomedical research, with 1,260 unique partners spanning 70 countries — well beyond Europe into global health and research infrastructure initiatives. Their network is particularly dense in Western European academic medicine but extends significantly into low- and middle-income countries through vaccine and infectious disease projects.

What sets them apart

LUMC combines the clinical infrastructure of a major teaching hospital with deep research capabilities in immunology, imaging, and regenerative medicine — a rare combination that allows them to take discoveries from bench to bedside within a single institution. Their 156-project H2020 track record and EUR 97M in funding place them among the top-funded medical centres in Europe, giving consortium builders confidence in their administrative and scientific delivery capacity. For partners seeking clinical validation sites, access to patient cohorts, or biobanking infrastructure, LUMC offers scale and expertise that few European medical centres can match.

Highlights from their portfolio

• RETHRIM
  Coordinated with EUR 2.3M budget — addresses the difficult clinical challenge of tissue regeneration in graft-versus-host disease, showcasing LUMC's strength in translational stem cell medicine.
• NOMA-MRI
  Coordinated with EUR 2.3M over 6 years — developing novel materials for MRI improvement, representing LUMC's push into advanced medical imaging technology.
• BRIDGES
  Coordinated a 6-year breast cancer risk genetics study combining genetic sequencing with lifestyle risk factors and predictive modelling — a prime example of their precision medicine direction.